MCM
PCRX icon

Marsico Capital Management’s Pacira BioSciences PCRX Stock Holding History

Marsico Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-46,992
Closed -$2.15M – 89
2017
Q4 		$2.15M Buy
46,992
+8,317
+22% +$330K 0.09% 83
2017
Q3 		$1.45M Hold
38,675
– – 0.06% 89
2017
Q2 		$1.84M Hold
38,675
– – 0.08% 95
2017
Q1 		$1.76M Buy
+38,675
New +$1.67M 0.08% 93
2016
Q3 		– Sell
-531,944
Closed -$17.9M – 97
2016
Q2 		$17.9M Sell
531,944
-511,367
-49% -$25.1M 0.62% 31
2016
Q1 		$55.3M Sell
1,043,311
-537,388
-34% -$31.4M 1.64% 18
2015
Q4 		$121M Sell
1,580,699
-889,841
-36% -$50.4M 2.15% 20
2015
Q3 		$102M Buy
2,470,540
+192,560
+8% +$11.8M 1.06% 26
2015
Q2 		$161M Buy
2,277,980
+331,788
+17% +$26.1M 1.42% 27
2015
Q1 		$173M Buy
1,946,192
+270,506
+16% +$27.4M 1.46% 25
2014
Q4 		$149M Buy
1,675,686
+168,701
+11% +$16M 1.19% 27
2014
Q3 		$146M Buy
1,506,985
+430,601
+40% +$41.9M 1.14% 30
2014
Q2 		$98.9M Buy
1,076,384
+134,258
+14% +$10.2M 0.72% 30
2014
Q1 		$65.9M Buy
942,126
+693,486
+279% +$47.2M 0.48% 44
2013
Q4 		$14.3M Buy
248,640
+226,110
+1,004% +$11.9M 0.1% 81
2013
Q3 		$1.08M Buy
+22,530
New +$821K 0.01% 98

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Marsico Capital Management's PCRX Position: Q1 2018 in Review

Marsico Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2018, closing a stake of 46,992 shares — an estimated $2.15M sold.

Marsico Capital Management first reported a position in PCRX in Q3 2013 and held it in 16 quarters. The position peaked at $173M in Q1 2015. 168 funds tracked by Wall St. Rank hold PCRX as of Q1 2018.

  • Marsico Capital Management reported no remaining Pacira BioSciences position as of Q1 2018 after selling out during the quarter.
  • Marsico Capital Management sold 46,992 Pacira BioSciences shares in Q1 2018, an estimated $2.15M.
  • Marsico Capital Management first reported a position in Pacira BioSciences in Q3 2013 and held it in 16 quarters.
  • Marsico Capital Management's Pacira BioSciences position peaked at $173M in Q1 2015.
  • 168 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2018.

Based on Marsico Capital Management's 13F filing for Q1 2018, filed 15 May 2018.